GlycoMimetics

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

GlycoMimetics reports strong Q4 performance and optimistic clinical advancements

GlycoMimetics delivered a robust performance in Q4 2022, driven by positive clinical outcomes and strategic financial decisions. The company's focus on uproleselan and promising interim utility analysis sets a solid foundation for future growth. While challenges like managing expenses and meeting trial milestones exist, GlycoMimetics is well-positioned to capitalize on opportunities in the biopharmaceutical sector.

GlycoMimetics excels in AML trials, secures funding for future growth

GlycoMimetics showcased strong performance in both clinical trials and financial standing, positioning the company well for future growth.
While challenges in managing expenses and navigating industry complexities exist, opportunities for expansion and innovation through partnerships are promising.

GlycoMimetics advances clinical trials and secures funding until late 2024

GlycoMimetics showcased strong progress in their clinical trials and financial stability during the Q2 2023 Earnings Call. With FDA clearance for Phase III uproleselan study and a cash runway until late 2024, the company is well-positioned for future growth. Challenges include successful trial execution and maintaining financial discipline.

GlycoMimetics progresses in AML trials, eyes positive Phase III results

GlycoMimetics demonstrated strong performance in advancing its clinical pipeline, with a focus on uproleselan in AML.
While facing challenges like delays in studies and increased expenses, the company remains optimistic about future prospects.
Opportunities lie in presenting data at conferences, exploring market expansion, and anticipating positive Phase III results by Q2 2024.

GlycoMimetics reports progress in trials and financial strength for growth

GlycoMimetics' Q4 2023 earnings call showcased positive clinical trial outcomes, strong financial standing, and a strategic focus on addressing unmet medical needs. The company's upcoming milestones, including the Phase III trial results and NDA submission, indicate promising growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of GlycoMimetics Inc. GLYC, -1.30% fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc.

GlycoMimetics stock down 53% after Phase 3 trial failure

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints.

GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2019 Results - Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlycoMimetics Enters Oversold Territory

GlycoMimetics has an outlicensed lead candidate targeting VOC in SCD patients.

GlycoMimetics In Vaso-Occlusive Crisis Of Sickle Cell Disease Has Decent Potential

Today, we look at an interesting small-cap developmental concern with a couple of compounds in late-stage development.

GlycoMimetics: An Investment Update

GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2019 Results - Earnings Call Transcript

As an innovator of carbohydrate-based medicines, GlycoMimetics is powering an enriched therapeutic pipeline for various cancers and medical conditions.

GlycoMimetics: Forecasting The Clinical Binary For Rivipansel

News for GlycoMimetics Stock (GLYC)